Ursocholanic Acid

Ursocholanic Acid

SCHEMBL1688735

CC(CCC(=O)O)C1CCC2C3CCC4CCCCC4(C)C3CCC12C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPBAR1 Q8TDU6 7/20 1.00
EPHA2 P29317 3/20 1.00
HSD17B10 Q99714 3/20 1.00
TDP1 Q9NUW8 3/20 1.00
AKR1B10 O60218 2/20 1.00
AKR1B1 P15121 2/20 1.00
LMNA P02545 2/20 1.00
EFNA1 P20827 1/20 1.00
PSEN1 P49768 1/20 1.00
PSEN2 P49810 1/20 1.00
APH1B Q8WW43 1/20 1.00
NCSTN Q92542 1/20 1.00
APH1A Q96BI3 1/20 1.00
PSENEN Q9NZ42 1/20 1.00
MEN1 O00255 1/20 1.00
KMT2A Q03164 1/20 1.00
VDR P11473 4/20 0.74
CASP7 P55210 3/20 0.74
TP53 P04637 2/20 0.74
MAPK1 P28482 2/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ursocholanic Acid SCHEMBL19313776 1.00 GPBAR1 (1.00) GPBAR1EPHA2HSD17B10TDP1AKR1B10
Ursocholanic Acid SCHEMBL190519 1.00 GPBAR1 (1.00) GPBAR1EPHA2HSD17B10TDP1AKR1B10
Ursocholanic Acid SCHEMBL16084677 1.00 GPBAR1 (1.00) GPBAR1EPHA2HSD17B10TDP1AKR1B10
Ursocholanic Acid SCHEMBL13811793 1.00 GPBAR1 (1.00) GPBAR1EPHA2HSD17B10TDP1AKR1B10
Ursocholanic Acid SCHEMBL25023120 1.00 GPBAR1 (1.00) GPBAR1EPHA2HSD17B10TDP1AKR1B10
Ursocholanic Acid SCHEMBL25023044 1.00 GPBAR1 (1.00) GPBAR1EPHA2HSD17B10TDP1AKR1B10
Ursocholanic Acid SCHEMBL5556804 1.00 GPBAR1 (1.00) GPBAR1EPHA2HSD17B10TDP1AKR1B10
Ursocholanic Acid SCHEMBL25021694 1.00 GPBAR1 (1.00) GPBAR1EPHA2HSD17B10TDP1AKR1B10
Ursocholanic Acid SCHEMBL22871921 1.00 GPBAR1 (1.00) GPBAR1EPHA2HSD17B10TDP1AKR1B10
Ursocholanic Acid SCHEMBL18575999 1.00 GPBAR1 (1.00) GPBAR1EPHA2HSD17B10TDP1AKR1B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023213540-A1 PROCESS FOR THE PREPARATION OF CHOLIC ACID DERIVATIVES CHEMELECTIVA S.R.L. (IT) 2023-11-09 WO disclosed
EP-2893922-B1 Pharmaceutical formulations for the treatment of pulmonary arterial hypertension HEART BIOTECH PHARMA LTD (GB) 2021-07-14 EP disclosed
EP-3285875-B1 METHODS FOR THE SYNTHESIS OF CERAGENINS UNIV BRIGHAM YOUNG (US) 2020-11-11 EP disclosed
US-10245244-B2 Pharmaceutical formulations for the treatment of pulmonary arterial hypertension HEART BIOTECH PHARMA LIMITED (GB) 2019-04-02 US disclosed
US-9146467-B2 Coating compositions MERCK PATENT GMBH (DE) 2015-09-29 US disclosed
US-9146467-B2 Coating compositions MERCK PATENT GMBH (DE) 2015-09-29 US disclosed
US-20150196516-A1 PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION HEART BIOTECH PHARMA LIMITED (GB) 2015-07-16 US disclosed
EP-2893922-A1 Pharmaceutical formulations for the treatment of pulmonary arterial hypertension Heart Biotech Pharma Limited (GB) 2015-07-15 EP disclosed
US-20130236833-A1 COATING COMPOSITIONS AZ ELECTRONIC MATERIALS USA CORP. (US) 2013-09-12 US disclosed
US-20130236833-A1 COATING COMPOSITIONS AZ ELECTRONIC MATERIALS USA CORP. (US) 2013-09-12 US disclosed
US-8455176-B2 Coating composition AZ ELECTRONIC MATERIALS USA CORP. (US) 2013-06-04 US disclosed
US-8455176-B2 Coating composition AZ ELECTRONIC MATERIALS USA CORP. (US) 2013-06-04 US disclosed
WO-2012047495-A2 METHODS FOR PREPARING SYNTHETIC BILE ACIDS AND COMPOSITIONS COMPRISING THE SAME KYTHERA BIOPHARMACEUTICALS, INC. (US) 2012-04-12 WO disclosed
WO-2010055406-A2 COATING COMPOSITIONS AZ ELECTRONIC MATERIALS USA CORP. (US) 2010-05-20 WO disclosed
US-20100119972-A1 COATING COMPOSITION MERCK PATENT GMBH (DE) 2010-05-13 US disclosed
US-20100119972-A1 COATING COMPOSITION MERCK PATENT GMBH (DE) 2010-05-13 US disclosed
EP-1817325-B1 SULFATED MOLECULAR UMBRELLAS CONTAINING 6-200 CHOLANIC ACID (DERIVATIVE) UNITS AS ANTI-HIV AND ANTI-HSV AGENTS UNIV LEHIGH (US) 2009-01-21 EP disclosed
US-20070232576-A1 Sulfated molecular umbrellas as anti-HIV and anti-HSV agents LEHIGH UNIVERSITY (US) 2007-10-04 US disclosed
US-20070232576-A1 Sulfated molecular umbrellas as anti-HIV and anti-HSV agents LEHIGH UNIVERSITY (US) 2007-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232576-A1 Sulfated molecular umbrellas as anti-HIV and anti-HSV agents RPL17, SSU72, RPL27A GPBAR1 414/4885EPHA2 1382/4885HSD17B10 471/4885
US-20100119972-A1 COATING COMPOSITION S100A9, CAPG, C5 GPBAR1 1101/4885EPHA2 24/4885HSD17B10 3969/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.